Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Amylyx Pharmaceuticals

08/05/2025 14:32

Amylyx Pharmaceuticals Inc AMLX.OQ reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of four analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -55 cents to -43 cents per share.

Reported revenue was zero​; analysts expected zero.

Amylyx Pharmaceuticals Inc's reported EPS for the quarter was a loss of 42 cents​.

The company reported a quarterly loss of $35.91 million.

Amylyx Pharmaceuticals Inc shares had risen by 37.6% this quarter and gained 28.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 23.4% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $10.00

This summary was machine generated from LSEG data May 8 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.47
-0.42
Beat
Dec. 31 2024
-0.52
-0.55
Missed
Sep. 30 2024
-0.71
-1.07
Missed
Jun. 30 2024
-0.73
-0.73
Met